PDS Biotechnology – Top-Line Data From Its Lead Candidate Points To Promising Future For This Company

Frank Bedu-Addo, Ph.D., CEO & Director of PDS Biotechnology PDSB, was recently a guest on Benzinga’s All-Access.

PDS Biotech is a clinical stage biopharmaceutical company with a growing pipeline of cancer immunotherapies and infectious disease vaccines. The company’s therapies attempt to harness the power of T cells to address some of the most devastating illnesses that exist. Scientists at PDS Biotech designed novel, proprietary cationic, lipid-based nanoparticle platform technologies to overcome the barriers that tend to limit the effectiveness of traditional T cell therapies.

Dr. Bedu-Addo spoke about the numerous trials the company has underway, including promising top line data from its lead drug candidate.

Watch the full interview here:

Featured photo by Braňo on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.